NCT00118274View on ClinicalTrials.gov

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

incomplete Freund's adjuvant

Given intradermally and subcutaneously

BIOLOGICAL

melanoma helper peptide vaccine

Given intradermally and subcutaneously

BIOLOGICAL

multi-epitope melanoma peptide vaccine

Given intradermally and subcutaneously

BIOLOGICAL

tetanus toxoid helper peptide

Given intradermally and subcutaneously

DRUG

cyclophosphamide

Given IV

Trial Locations (3)

22908

University of Virginia Cancer Center, Charlottesville

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Craig L Slingluff, Jr

OTHER

NCT00118274 - Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter